Profile data is unavailable for this security.
About the company
ZyVersa Therapeutics, Inc. is a clinical-stage specialty biopharmaceutical company. The Company is focused on leveraging advanced technologies to develop drugs for patients with chronic renal or inflammatory diseases. Its lead renal drug candidate Cholesterol Efflux Mediator VAR 200 (2-hydroxypropyl-beta-cyclodextrin or 2HBCD) is in development to treat multiple renal indications. Its lead anti-inflammatory drug candidate, Inflammasome ASC Inhibitor IC 100, is a humanized monoclonal antibody in development to treat multiple inflammatory diseases. Its renal pipeline is initially focused on rare, chronic glomerular diseases. Its lead indication for VAR 200 is focal segmental glomerulosclerosis (FSGS). VAR 200’s active ingredient, 2HBCD, is comprised of seven sugar molecules bound together in a 3-D ring with a hydrophobic core and hydrophilic exterior. VAR 200 mediates cholesterol efflux both passively and actively by interacting with hydrophilic components of the glomerular membrane.
- Revenue in USD (TTM)0.00
- Net income in USD-105.53m
- Incorporated2021
- Employees7.00
- LocationZyversa Therapeutics Inc2200 N. Commerce Parkway, Suite 208WESTON 33326United StatesUSA
- Phone+1 (754) 231-1688
- Fax+1 (845) 818-3588
- Websitehttps://www.zyversa.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cingulate Inc | 0.00 | -22.50m | 4.17m | 13.00 | -- | 1.04 | -- | -- | -22.66 | -22.66 | 0.00 | 0.6419 | 0.00 | -- | -- | 0.00 | -355.56 | -- | -1,198.96 | -- | -- | -- | -- | -- | -- | -33.88 | 0.0054 | -- | -- | -- | -33.14 | -- | -- | -- |
| Protagenic Therapeutics Inc | 0.00 | -6.01m | 4.21m | -- | -- | 1.98 | -- | -- | -1.37 | -1.37 | 0.00 | 0.4808 | 0.00 | -- | -- | -- | -117.26 | -74.49 | -140.56 | -92.56 | -- | -- | -- | -- | -- | -11.50 | 0.00 | -- | -- | -- | -40.64 | -- | -- | -- |
| Reliv International Inc | 35.13m | -175.48k | 4.23m | 208.00 | -- | 0.611 | 10.59 | 0.1205 | -0.1005 | -0.1005 | 20.12 | 6.55 | 2.09 | 8.02 | 228.49 | -- | -1.05 | -4.65 | -1.47 | -6.06 | 40.90 | 41.98 | -0.4996 | -2.33 | 1.07 | -- | 0.1064 | -- | -2.94 | -9.37 | 76.65 | -- | -35.85 | -- |
| Regen BioPharma Inc | 236.58k | -851.69k | 4.26m | 1.00 | -- | -- | -- | 18.00 | -0.2271 | -0.2271 | 0.0633 | -1.26 | 0.8644 | -- | 3.98 | 236,580.00 | -327.54 | -104.36 | -- | -- | -- | -- | -378.93 | -275.00 | -- | -1.32 | -- | -- | 0.4416 | 18.79 | -58.11 | -- | -- | -- |
| Theriva Biologics Inc | 0.00 | -19.04m | 4.28m | 21.00 | -- | 0.1352 | -- | -- | -1.15 | -1.15 | 0.00 | 1.99 | 0.00 | -- | -- | 0.00 | -32.65 | -36.95 | -37.33 | -40.16 | -- | -- | -- | -- | -- | -- | 0.0064 | -- | -- | -- | 8.37 | -- | 95.91 | -- |
| Artelo Biosciences Inc | 0.00 | -9.60m | 4.28m | 5.00 | -- | 0.4484 | -- | -- | -3.13 | -3.13 | 0.00 | 2.95 | 0.00 | -- | -- | 0.00 | -66.62 | -- | -70.40 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.87 | -- | -- | -- |
| Zyversa Therapeutics Inc | 0.00 | -105.53m | 4.38m | 7.00 | -- | 0.3906 | -- | -- | -1,791.54 | -1,791.54 | 0.00 | 13.44 | 0.00 | -- | -- | 0.00 | -142.87 | -- | -164.77 | -- | -- | -- | -- | -- | -- | -17,576.86 | 0.00 | -- | -- | -- | -340.15 | -- | -- | -- |
| Palisade Bio Inc | 0.00 | -13.49m | 4.39m | 9.00 | -- | 0.396 | -- | -- | -24.67 | -24.67 | 0.00 | 11.82 | 0.00 | -- | -- | 0.00 | -96.63 | -132.36 | -111.78 | -165.45 | -- | -- | -- | -27,892.32 | -- | -874.31 | 0.00 | -- | -- | -0.7814 | 13.74 | -- | 18.53 | -- |
| AccuStem Sciences Inc | 0.00 | -1.74m | 4.42m | 3.00 | -- | -- | -- | -- | -0.1537 | -0.1537 | 0.00 | -0.2309 | 0.00 | -- | -- | 0.00 | -1,168.46 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 45.26 | -- | -- | -- |
| Hoth Therapeutics Inc | 0.00 | -7.70m | 4.52m | 2.00 | -- | 0.5196 | -- | -- | -2.02 | -2.02 | 0.00 | 1.78 | 0.00 | -- | -- | 0.00 | -70.17 | -157.07 | -77.15 | -177.32 | -- | -- | -- | -- | -- | -50.67 | 0.00 | -- | -- | -- | 31.01 | -- | -- | -- |
| Evoke Pharma Inc | 6.11m | -7.13m | 4.54m | 4.00 | -- | 1.30 | -- | 0.7438 | -1.83 | -1.83 | 1.28 | 0.4068 | 0.5429 | 0.5113 | 5.71 | 1,526,428.00 | -63.39 | -100.48 | -76.67 | -151.10 | 96.01 | -- | -116.76 | -480.52 | 5.35 | -19.25 | 0.5884 | -- | 106.51 | -- | 5.25 | -- | -- | -- |
| Genprex Inc | 0.00 | -27.63m | 4.64m | 26.00 | -- | 0.4852 | -- | -- | -19.18 | -19.18 | 0.00 | 4.55 | 0.00 | -- | -- | 0.00 | -153.97 | -92.06 | -202.83 | -98.32 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -29.99 | -- | -7.13 | -- |
| Tonix Pharmaceuticals Holding Corp | 10.25m | -98.59m | 4.69m | 103.00 | -- | 0.0239 | -- | 0.4573 | -177.41 | -177.41 | 9.46 | 46.94 | 0.0652 | -- | -- | 99,514.56 | -62.71 | -59.46 | -70.20 | -65.92 | 37.55 | -- | -961.87 | -5,126.73 | 0.8666 | -- | 0.0767 | -- | -- | -- | 0.1874 | -- | 320.57 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Two Sigma Securities LLCas of 31 Mar 2024 | 3.12k | 0.37% |
| Cubist Systematic Strategies LLCas of 31 Mar 2024 | 2.94k | 0.35% |
| UBS Securities LLCas of 31 Mar 2024 | 1.99k | 0.24% |
| HRT Financial LLCas of 31 Mar 2024 | 1.32k | 0.16% |
| Jane Street Capital LLCas of 31 Mar 2024 | 1.21k | 0.15% |
| Tower Research Capital LLCas of 31 Mar 2024 | 854.00 | 0.10% |
| Wells Fargo Bank, NA (Private Banking)as of 31 Mar 2024 | 1.00 | 0.00% |
| Anson Funds Management LPas of 31 Mar 2024 | 0.00 | 0.00% |
| EdgeHill Partnersas of 31 Dec 2023 | 0.00 | 0.00% |
| Citadel Securities LLCas of 31 Mar 2024 | 0.00 | 0.00% |
